Company Encyclopedia
View More
name
JIUDIAN PHARMACEUTICAL
300705.SZ
Hunan Jiudian Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. Its products portfolio includes Pantoprazole Sodium Enteric-coated, Ferrous Succinate, Rosuvastatin Calcium, Ebastine, and Rabeprazole Sodium Enteric-coated Tablets; and Acetylcysteine Granules, Potassium Sodium Hydrogen Citrate Granules, Loxoprofen Sodium Gel Patch, and Ketoprofen gel patch. The company also offers drugs for analgesic, cardio-cerebrovascular, anti-infection, digestive and urinary system, and breathing and anti-allergy.
3.144 T
300705.SZMarket value -Rank by Market Cap -/-

Financial Score

09/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking42/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE18.54%A
    • Profit Margin15.36%A
    • Gross Margin74.70%A
  • Growth ScoreC
    • Revenue YoY3.64%C
    • Net Profit YoY-7.68%C
    • Total Assets YoY13.27%B
    • Net Assets YoY13.09%B
  • Cash ScoreC
    • Cash Flow Margin650.92%C
    • OCF YoY3.64%C
  • Operating ScoreB
    • Turnover0.88B
  • Debt ScoreB
    • Gearing Ratio26.58%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    JIUDIAN PHARMACEUTICAL and others establish an innovative pharmaceutical technology company

    According to the Qichacha APP, recently, Hunan JIUDIAN SHANNUO Innovative Pharmaceutical Technology Co., Ltd. was established, with Zhu Zhihong as the legal representative and a registered capital of 100 million yuan. The business scope includes: medical research and experimental development; engineering and technology research and experimental development, etc. Qichacha's equity penetration shows that the company is jointly held by JIUDIAN PHARMACEUTICAL, Changsha Xiangjiang Shannuo Venture Capital Partnership, and others

    Zhitong·
    SZ
    300705
    -0.87%
    Zhitong·
    SZ
    300705
    -0.87%

    JIUDIAN PHARMACEUTICAL released its performance for the first three quarters, with a net profit attributable to the parent company of 406 million yuan, a decrease of 9.64%

    According to the Zhitong Finance APP, JIUDIAN PHARMACEUTICAL released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 2.268 billion yuan, a year-on-year increase of 5.69%. The net profit attributable to shareholders of the listed company was 406 million yuan, a year-on-year decrease of 9.64%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 391 million yuan, a year-on-year decrease of 6.47%. The basic earnings per share were 0.82 yuan

    Zhitong·
    SZ
    300705
    -0.87%
    Zhitong·
    SZ
    300705
    -0.87%

    JIUDIAN PHARMACEUTICAL established a ginseng e-commerce company in Hunan

    According to the Qichacha APP, recently, Hunan Ginseng Manman E-commerce Co., Ltd. was established, with Zheng Liang as the legal representative. The business scope includes: retail of cosmetics; internet sales; advertising design and agency; brand management, etc. Qichacha's equity penetration shows that the company is wholly owned by JIUDIAN PHARMACEUTICAL

    Zhitong·
    SZ
    300705
    -0.87%
    Zhitong·
    SZ
    300705
    -0.87%

    JIUDIAN PHARMACEUTICAL: Plans to use its own funds of 50 million yuan to jointly invest with Xiangjiang Shannuo and Jiu Zhi Qing Yan to establish Hunan Jiu Dian Shannuo Innovative Pharmaceutical Technology Co., Ltd

    JIUDIAN PHARMACEUTICAL announced that the company plans to use its own funds of 50 million yuan to jointly invest with Changsha Xiangjiang Shannuo Venture Capital Partnership and Hainan Jiu Zhi Qing Yan Technology Partnership to establish Hunan Jiu Dian Shannuo Innovative Pharmaceutical Technology Co., Ltd. The registered capital of Jiu Dian Shannuo is 100 million yuan, with the company holding 50%, Xiangjiang Shannuo holding 30%, and Jiu Zhi Qing Yan holding 20%. This investment constitutes a related party transaction but does not constitute a major asset reorganization

    Zhitong·
    SZ
    300705
    -0.87%
    Zhitong·
    SZ
    300705
    -0.87%

    JIUDIAN PHARMACEUTICAL has been approved to conduct clinical trials for two drugs

    According to the Zhitong Finance APP, JIUDIAN PHARMACEUTICAL announced that the company recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. After completing the relevant preparatory work, it will carry out clinical trial research. The approved clinical trials include: JIZM01 for clinical trials of closed soft tissue contusions and joint sprains, and JIZM02 for clinical trials of shoulder periarthritis

    Zhitong·
    SZ
    300705
    -0.87%
    Zhitong·
    SZ
    300705
    -0.87%
    © 2025 Longbridge｜Disclaimer